167 related articles for article (PubMed ID: 14650936)
1. The development of supportive-care agents for patients with cancer.
Neumann TK; Foote M
Biotechnol Annu Rev; 2003; 9():397-417. PubMed ID: 14650936
[TBL] [Abstract][Full Text] [Related]
2. Managing hematologic toxicities: novel therapies.
Nirenberg A
Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
[TBL] [Abstract][Full Text] [Related]
3. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
Ong JP; Younossi ZM
Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
[TBL] [Abstract][Full Text] [Related]
4. Annual review of cytokines in cancer management. Summaries of selected studies of darbepoetin alfa, pegfilgrastim, palifermin, and other cytokines presented at six major meetings held in 2004.
J Support Oncol; 2005; 3(2 Suppl 1):3-84. PubMed ID: 15984088
[No Abstract] [Full Text] [Related]
5. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
[TBL] [Abstract][Full Text] [Related]
6. Filgrastim in patients with neutropenia: potential effects on quality of life.
Lyman GH; Kuderer NM
Drugs; 2002; 62 Suppl 1():65-78. PubMed ID: 12479595
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
8. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
Collantes RS; Younossi ZM
J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
[TBL] [Abstract][Full Text] [Related]
9. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia.
Petros WP
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):1S-2S; quiz 20S-23S. PubMed ID: 12921215
[No Abstract] [Full Text] [Related]
10. [New generation cytokines to prevent anemia and febrile neutropenia].
Fayette J; Blay JY
Bull Cancer; 2006 May; 93(5):483-7. PubMed ID: 16777626
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced neutropenia: new approaches to an old problem.
Ozer H
Semin Oncol; 2003 Aug; 30(4 Suppl 13):1-2. PubMed ID: 14508713
[No Abstract] [Full Text] [Related]
12. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
Barosi G; Bosi A; Abbracchio MP; Danesi R; Genazzani A; Corradini P; Pane F; Tura S
Haematologica; 2011 Jul; 96(7):937-42. PubMed ID: 21719882
[No Abstract] [Full Text] [Related]
13. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
14. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
[TBL] [Abstract][Full Text] [Related]
15. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Cases A
Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
[TBL] [Abstract][Full Text] [Related]
16. Pegfilgrastim.
Willis F; Pettengell R
Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
[TBL] [Abstract][Full Text] [Related]
17. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
Biganzoli L; Untch M; Skacel T; Pico JL
Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
[TBL] [Abstract][Full Text] [Related]
18. Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy.
Poonawalla IB; Piller LB; Lairson DR; Chan W; Du XL
Int J Gynecol Cancer; 2016 Jan; 26(1):95-103. PubMed ID: 26509851
[TBL] [Abstract][Full Text] [Related]
19. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.
Molineux G
Anticancer Drugs; 2003 Apr; 14(4):259-64. PubMed ID: 12679729
[TBL] [Abstract][Full Text] [Related]
20. [Recent advances in the clinical use of cytokines].
Kimura F
Rinsho Ketsueki; 2006 Apr; 47(4):287-93. PubMed ID: 16715963
[No Abstract] [Full Text] [Related]
[Next] [New Search]
